ACM
OBIO icon

Atika Capital Management’s Orchestra BioMed OBIO Stock Holding History

Atika Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-64,651
Closed -$453K – 92
2023
Q2 		$453K Buy
+64,651
New +$981K 0.05% 83

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Atika Capital Management's OBIO Position: Q3 2023 in Review

Atika Capital Management sold out of Orchestra BioMed (OBIO) in Q3 2023, closing a stake of 64,651 shares — an estimated $453K sold.

Atika Capital Management first reported a position in OBIO in Q2 2023 and held it in 1 quarter. The position peaked at $453K in Q2 2023. 42 funds tracked by Wall St. Rank hold OBIO as of Q3 2023.

  • Atika Capital Management reported no remaining Orchestra BioMed position as of Q3 2023 after selling out during the quarter.
  • Atika Capital Management sold 64,651 Orchestra BioMed shares in Q3 2023, an estimated $453K.
  • Atika Capital Management first reported a position in Orchestra BioMed in Q2 2023 and held it in 1 quarter.
  • Atika Capital Management's Orchestra BioMed position peaked at $453K in Q2 2023.
  • 42 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2023.

Based on Atika Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.